DK2004807T3 - Sammensætninger til fremstillingen af modne dendritceller - Google Patents
Sammensætninger til fremstillingen af modne dendritceller Download PDFInfo
- Publication number
- DK2004807T3 DK2004807T3 DK07723717.0T DK07723717T DK2004807T3 DK 2004807 T3 DK2004807 T3 DK 2004807T3 DK 07723717 T DK07723717 T DK 07723717T DK 2004807 T3 DK2004807 T3 DK 2004807T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- cell
- dcs
- agonist
- immature
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 16
- 210000001787 dendrite Anatomy 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 210000004443 dendritic cell Anatomy 0.000 claims description 302
- 210000004027 cell Anatomy 0.000 claims description 105
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 69
- 229960002986 dinoprostone Drugs 0.000 claims description 69
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 53
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 49
- 230000035800 maturation Effects 0.000 claims description 39
- 239000000427 antigen Substances 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 210000001616 monocyte Anatomy 0.000 claims description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 238000000338 in vitro Methods 0.000 claims description 23
- 229940124613 TLR 7/8 agonist Drugs 0.000 claims description 19
- 238000011534 incubation Methods 0.000 claims description 18
- FBFJOZZTIXSPPR-UHFFFAOYSA-N 1-(4-aminobutyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CCCCN)C3=C(N)N=C21 FBFJOZZTIXSPPR-UHFFFAOYSA-N 0.000 claims description 17
- 230000004936 stimulating effect Effects 0.000 claims description 16
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 13
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 13
- 238000003306 harvesting Methods 0.000 claims description 13
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims description 12
- 210000001165 lymph node Anatomy 0.000 claims description 12
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 9
- 108090000978 Interleukin-4 Proteins 0.000 claims description 9
- 239000000556 agonist Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000011068 loading method Methods 0.000 claims description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 102000003816 Interleukin-13 Human genes 0.000 claims description 8
- 108090000176 Interleukin-13 Proteins 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000004069 differentiation Effects 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 7
- 210000005259 peripheral blood Anatomy 0.000 claims description 7
- 239000011886 peripheral blood Substances 0.000 claims description 7
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 6
- 210000005087 mononuclear cell Anatomy 0.000 claims description 6
- 210000003643 myeloid progenitor cell Anatomy 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 230000011748 cell maturation Effects 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 231100000588 tumorigenic Toxicity 0.000 claims description 2
- 230000000381 tumorigenic effect Effects 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 5
- RXNTZIJLOZMJTM-UHFFFAOYSA-N 2-(2h-quinolin-1-yl)ethanol Chemical compound C1=CC=C2N(CCO)CC=CC2=C1 RXNTZIJLOZMJTM-UHFFFAOYSA-N 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 45
- 102100040247 Tumor necrosis factor Human genes 0.000 description 44
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 42
- 206010028980 Neoplasm Diseases 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
- 102000004127 Cytokines Human genes 0.000 description 20
- 108090000695 Cytokines Proteins 0.000 description 20
- 108090000174 Interleukin-10 Proteins 0.000 description 17
- 210000004698 lymphocyte Anatomy 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 102000003777 Interleukin-1 beta Human genes 0.000 description 12
- 108090000193 Interleukin-1 beta Proteins 0.000 description 12
- 108090001005 Interleukin-6 Proteins 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 12
- 102100035793 CD83 antigen Human genes 0.000 description 11
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 11
- 108700012920 TNF Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 238000004520 electroporation Methods 0.000 description 10
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 9
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 9
- 102000008070 Interferon-gamma Human genes 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 9
- 229960003130 interferon gamma Drugs 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000035899 viability Effects 0.000 description 9
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 7
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 7
- 108010065805 Interleukin-12 Proteins 0.000 description 7
- 102000013462 Interleukin-12 Human genes 0.000 description 7
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 108010004729 Phycoerythrin Proteins 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 7
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 101150013553 CD40 gene Proteins 0.000 description 6
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 108010029697 CD40 Ligand Proteins 0.000 description 5
- 102100032937 CD40 ligand Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 4
- 238000011510 Elispot assay Methods 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 4
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 208000021039 metastatic melanoma Diseases 0.000 description 4
- 230000001617 migratory effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000002617 apheresis Methods 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- -1 clone: B8.12.2 Proteins 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000007420 reactivation Effects 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 2
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 2
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 2
- 229940127174 UCHT1 Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000719 anti-leukaemic effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 108010065889 glycyl-leucyl-cysteinyl-threonyl-leucyl-valyl-alanyl-methionyl-leucine Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 239000003970 toll like receptor agonist Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- RDFLLVCQYHQOBU-GPGGJFNDSA-O Cyanin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@H](CO)O1)c1c(-c2cc(O)c(O)cc2)[o+]c2c(c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O3)cc(O)c2)c1 RDFLLVCQYHQOBU-GPGGJFNDSA-O 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- DSIFMINXCSHZPQ-UHFFFAOYSA-M FUN-1 Chemical compound [I-].S1C2=CC=CC=C2[N+](C)=C1C=C(C1=CC=CC=C11)C=C(Cl)N1C1=CC=CC=C1 DSIFMINXCSHZPQ-UHFFFAOYSA-M 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101100059511 Homo sapiens CD40LG gene Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001397173 Kali <angiosperm> Species 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102100034924 T-lymphocyte activation antigen CD86 Human genes 0.000 description 1
- 229940124614 TLR 8 agonist Drugs 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 230000002187 allostimulatory effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- RDFLLVCQYHQOBU-ZOTFFYTFSA-O cyanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=[O+]C1=CC(O)=C2)C=3C=C(O)C(O)=CC=3)=CC1=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 RDFLLVCQYHQOBU-ZOTFFYTFSA-O 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000034964 establishment of cell polarity Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 229940040731 human interleukin-12 Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 210000000428 immunological synapse Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229950005634 loxoribine Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- CBHOWTTXCQAOID-UHFFFAOYSA-L sodium ethane formaldehyde mercury(2+) molecular iodine 2-sulfidobenzoate Chemical compound [Na+].[Hg++].C[CH2-].II.C=O.[O-]C(=O)c1ccccc1[S-] CBHOWTTXCQAOID-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Mycology (AREA)
Claims (15)
1. Fremgangsmåde til in vitro-modning af mindst én umoden dendritcelle, omfattende stimulering af den umodne dendritcelle med TNFa, IL-Ιβ, IFNy, en TLR7/8-agonist og prostaglandin E2 (PG).
2. Fremgangsmåden ifølge krav 1, yderligere omfattende stimulering af den umodne dendritcelle med en TLR3-agonist, fortrinsvis polyI:C.
3. Fremgangsmåden ifølge et hvilket som helst af kravene 1 eller 2, hvor substanserne er del af en sammensætning tilsat til dyrkningsmediet til den umodne dendritcelle.
4. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 3, hvor TLR7/8-agonisten er en imidazoquinilon-type immun-respons-modificerende forbindelse, fortrinsvis hvor den imidazoquinilon-type immun-respons-modificerende forbindelse er 4-amino-2-ethoxymethyl-a,a-dimethyl-lH-imidazol[4,5-c]quinolin-1-ethanol (R848).
5. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 4, hvor den umodne dendritcelle er en monocyt afledt umoden dendritcelle, fortrinsvis afledt fra humane perifere blod-mononuklære celler, monocytter, andre myeloid-progenitorceller, eller fra CD34 positive progenitorceller ved in v/'fro-differentiering til CD 14-positive celler, eller hvor den umodne dendritcelle er opnået direkte fra perifert blod.
6. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 5, hvor den umodne dendritcelle er opnået ved inkubering af humane perifere blod-mononukleære celler, monocytter eller andre myeloide progenitorceller med GM-CSF og IL-4 eller IL-13.
7. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 6, hvor den umodne dendritcelle er af human oprindelse.
8. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 7, omfattende følgende trin: a) fremstille mononukleære celler fra perifert blod, fortrinsvis hvor de mononukleære celler opnås ved leukopherese fra perifert blod, b) inkubere de mononukleære celler fra trin a) med GM-CSF og IL-4 eller IL-13, fortrinsvis hvor inkubationen tager 1 til 9, fortrinsvis 2 til 9, mere fortrinsvis 2 til 6 dage, c) inkubere cellerne opnået i trin b) med en cocktail omfattende TNFa, IL-1β, IFNy, en TLR7/8-agonist, prostaglandin E2 (PG), og, eventuelt, en TLR3-agonist, fortrinsvis poly I:C, fortrinsvis hvor inkubationen tager 12 til 72 timer, fortrinsvis 20 eller 24 timer, og d) høste den modne dendritcelle eller -celler.
9. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 8, hvor den modne dendritcelle eller -celler yderligere fyldes in vitro med ét eller flere antigener, fortrinsvis hvor antigenet eller antigenerne formodes at udløse effektor-T-cellemodningen inde i lymfeknuderne, mere fortrinsvis hvor fyldningen udføres ved at inkubere den modne dendritcelle eller -celler med mindst ét peptid af dette antigen eller ved transfektere dendritcellen eller -cellerne med antigen-kodende RNA eller DNA.
10. Population af modne dendritceller, opnåelig ved fremgangsmåden ifølge et hvilket som helst af kravene 1 til 6, 8 eller 9, hvor den umodne dendritcelle er af human oprindelse, og hvor TNFa anvendes ved en koncentration på 1 ng/ml til 50 ng/ml, IL-Ιβ anvendes ved en koncentration på 1 ng/ml til 50 ng/ml, IFNy anvendes ved en koncentration på 500 U/ml til 10000 U/ml, TLR7/8-agonisten anvendes ved en koncentration på 0,2 pg/ml til 5 pg/ml, PGE2 anvendes ved en koncentration på 50 ng/ml til 5000 ng/ml, og TLR3-agonisten anvendes ved en koncentration på 10 ng/ml til 50 ng/ml.
11. Farmaceutisk sammensætning omfattende populationen af modne dendritceller ifølge krav 10.
12. Populationen af modne dendritceller ifølge krav 10 til anvendelse i behandlingen af en sygdom valgt fra gruppen bestående af tumorigene sygdomme og infektionssygdomme.
13. Kombineret in vitro anvendelse af TNFa, IL-Ιβ, IFNy, en TLR7/8-agonist, prostaglandin E2 (PG), og, eventuelt, en TLR3-agonist, fortrinsvis poly I:C, til fremstillingen af mindst én moden dendritcelle.
14. Anvendelsen ifølge krav 13, hvor TLR7/8-agonisten er en imidazoquinilon-type immun-respons-modificerende forbindelse, fortrinsvis 4-amino-2-ethoxymethyl-a,a-dimethyl-lH-imidazol[4,5-c]quinolin-l-ethanol (R848).
15. Sammensætning omfattende TNFa, IL-Ιβ, IFNy, a TLR7/8 agonist, prostaglandin E2 (PG), og, eventuelt, en TLR3-agonist, fortrinsvis poly I:C, fortrinsvis hvor TLR7/8-agonisten er en imidazoquinilon-type immun-respons-modificerende forbindelse, fortrinsvis 4-amino-2-ethoxymethyl-a,a-dimethyl-lH-imidazol[4,5-c]quinolin-l-ethanol (R848).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06006373A EP1840206A1 (en) | 2006-03-28 | 2006-03-28 | Compositions for the preparation of mature dendritic cells |
| US82582206P | 2006-09-15 | 2006-09-15 | |
| PCT/EP2007/002773 WO2007110240A1 (en) | 2006-03-28 | 2007-03-28 | Compositions for the preparation of mature dendritic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2004807T3 true DK2004807T3 (da) | 2015-05-11 |
Family
ID=36441990
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15157220.3T DK2918673T3 (da) | 2006-03-28 | 2007-03-28 | Sammensætninger til fremstilling af modne dendritiske celler |
| DK07723717.0T DK2004807T3 (da) | 2006-03-28 | 2007-03-28 | Sammensætninger til fremstillingen af modne dendritceller |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15157220.3T DK2918673T3 (da) | 2006-03-28 | 2007-03-28 | Sammensætninger til fremstilling af modne dendritiske celler |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8679840B2 (da) |
| EP (4) | EP1840206A1 (da) |
| AU (1) | AU2007229640B2 (da) |
| CA (1) | CA2647622C (da) |
| CY (1) | CY1121448T1 (da) |
| DK (2) | DK2918673T3 (da) |
| ES (2) | ES2535835T3 (da) |
| HU (1) | HUE042138T2 (da) |
| PL (2) | PL2918673T3 (da) |
| PT (2) | PT2004807E (da) |
| SI (1) | SI2918673T1 (da) |
| TR (1) | TR201904207T4 (da) |
| WO (1) | WO2007110240A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1780220A1 (en) * | 2005-11-01 | 2007-05-02 | Charité - Universitätsmedizin Berlin | Use of CEACAM8-specific substances for treating autoimmune diseases and a method for screening substances which induce apoptosis |
| WO2010049152A1 (en) * | 2008-10-29 | 2010-05-06 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Novel composition for the preparation of mature dendritic cells |
| JP5855018B2 (ja) * | 2010-02-10 | 2016-02-09 | イミュニカム アーベー | 腫瘍細胞増殖を阻害するための改善された組成物 |
| CN102933228A (zh) * | 2010-03-15 | 2013-02-13 | 宾夕法尼亚大学董事会 | 制备和储存活化的、成熟树突细胞的体系和方法 |
| EP2617434A1 (en) * | 2012-01-20 | 2013-07-24 | Laboratorios Del. Dr. Esteve, S.A. | HIV-1 integrase deficient immunogens and methods for loading dendritic cells with said immunogens |
| HK1204275A1 (en) * | 2012-03-02 | 2015-11-13 | Laboratorios Del. Dr. Esteve, S.A. | Method for the preparation of dendritic cell vaccines |
| WO2014096033A1 (en) * | 2012-12-18 | 2014-06-26 | Immunicum Ab | Co-differentiation of monocytes from allogeneic donors |
| EP3145516A4 (en) * | 2014-05-20 | 2018-06-13 | Kiromic, LLC | Methods and compositions for treating malignancies with dendritic cells |
| WO2017002045A1 (en) | 2015-06-30 | 2017-01-05 | Stemlab, Sa | A viable cell population, method for production and uses thereof |
| WO2017109110A1 (en) * | 2015-12-23 | 2017-06-29 | Medigene Immunotherapies Gmbh | Dendritic cell composition |
| KR101946572B1 (ko) * | 2017-01-31 | 2019-02-11 | 주식회사 큐라티스 | 면역 관용성 플라즈마사이토이드 수지상 세포 및 그 제조방법 |
| GB201711379D0 (en) * | 2017-07-14 | 2017-08-30 | Univ Cape Town | Maturation of dendritic cells |
| KR102356510B1 (ko) * | 2017-09-05 | 2022-02-08 | 메디진 이뮤노테라피스 게엠바하 | 수지상 세포 효능 분석 |
| ES2769128T3 (es) * | 2017-09-20 | 2020-06-24 | Immunicum Ab | Células dendríticas alogénicas mejoradas para uso en el tratamiento de cáncer |
| CN109182384A (zh) * | 2018-09-30 | 2019-01-11 | 北京鼎成肽源生物技术有限公司 | 一种rff1细胞的构建方法 |
| CN115068598A (zh) * | 2022-04-25 | 2022-09-20 | 福建医科大学孟超肝胆医院(福州市传染病医院) | Tlr激动剂以及包含新生抗原的免疫原性组合物在制备药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6558951B1 (en) | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| PT1441591T (pt) * | 2001-09-06 | 2016-10-06 | Northwest Biotherapeutics Inc | Composições e métodos para ativaçao linfocitária de células dendríticas monocíticas e células para resposta th-1 |
| US20050003533A1 (en) * | 2003-05-08 | 2005-01-06 | Pawel Kalinski | Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use |
-
2006
- 2006-03-28 EP EP06006373A patent/EP1840206A1/en not_active Withdrawn
-
2007
- 2007-03-28 US US12/294,453 patent/US8679840B2/en active Active
- 2007-03-28 SI SI200732101T patent/SI2918673T1/sl unknown
- 2007-03-28 PT PT77237170T patent/PT2004807E/pt unknown
- 2007-03-28 ES ES07723717.0T patent/ES2535835T3/es active Active
- 2007-03-28 PL PL15157220T patent/PL2918673T3/pl unknown
- 2007-03-28 PT PT15157220T patent/PT2918673T/pt unknown
- 2007-03-28 HU HUE15157220A patent/HUE042138T2/hu unknown
- 2007-03-28 ES ES15157220T patent/ES2718525T3/es active Active
- 2007-03-28 TR TR2019/04207T patent/TR201904207T4/tr unknown
- 2007-03-28 AU AU2007229640A patent/AU2007229640B2/en not_active Ceased
- 2007-03-28 EP EP07723717.0A patent/EP2004807B1/en active Active
- 2007-03-28 WO PCT/EP2007/002773 patent/WO2007110240A1/en not_active Ceased
- 2007-03-28 PL PL07723717T patent/PL2004807T3/pl unknown
- 2007-03-28 EP EP18248089.7A patent/EP3517603A1/en not_active Withdrawn
- 2007-03-28 DK DK15157220.3T patent/DK2918673T3/da active
- 2007-03-28 CA CA2647622A patent/CA2647622C/en active Active
- 2007-03-28 DK DK07723717.0T patent/DK2004807T3/da active
- 2007-03-28 EP EP15157220.3A patent/EP2918673B1/en active Active
-
2014
- 2014-02-06 US US14/174,064 patent/US9512402B2/en not_active Expired - Fee Related
-
2016
- 2016-10-25 US US15/333,476 patent/US20170037372A1/en not_active Abandoned
-
2019
- 2019-03-20 CY CY20191100332T patent/CY1121448T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2004807T3 (pl) | 2015-07-31 |
| HUE042138T2 (hu) | 2019-06-28 |
| US20170037372A1 (en) | 2017-02-09 |
| US20100284976A1 (en) | 2010-11-11 |
| EP2004807B1 (en) | 2015-03-04 |
| SI2918673T1 (sl) | 2019-05-31 |
| DK2918673T3 (da) | 2019-04-01 |
| EP3517603A1 (en) | 2019-07-31 |
| US20140302096A1 (en) | 2014-10-09 |
| EP2918673B1 (en) | 2019-01-16 |
| US8679840B2 (en) | 2014-03-25 |
| PT2918673T (pt) | 2019-04-23 |
| PT2004807E (pt) | 2015-05-20 |
| US9512402B2 (en) | 2016-12-06 |
| AU2007229640B2 (en) | 2013-05-02 |
| AU2007229640A1 (en) | 2007-10-04 |
| EP2918673A1 (en) | 2015-09-16 |
| EP1840206A1 (en) | 2007-10-03 |
| CA2647622A1 (en) | 2007-10-04 |
| TR201904207T4 (tr) | 2019-05-21 |
| CY1121448T1 (el) | 2020-05-29 |
| CA2647622C (en) | 2017-04-18 |
| ES2535835T3 (es) | 2015-05-18 |
| ES2718525T3 (es) | 2019-07-02 |
| PL2918673T3 (pl) | 2019-08-30 |
| EP2004807A1 (en) | 2008-12-24 |
| WO2007110240A1 (en) | 2007-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2004807T3 (da) | Sammensætninger til fremstillingen af modne dendritceller | |
| Zobywalski et al. | Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70 | |
| CA2772280C (en) | Compositions and methods of preparing alloreactive cytotoxic t cells | |
| KR101415039B1 (ko) | 자기유래 활성화 림프구의 대량 증식을 위한 배지 조성물 및 배양방법 | |
| EP4363559A1 (en) | Cgmp compliant production and expansion of plasmacytoid dendritic cells from hematopoietic stem and progenitor cells | |
| Romain et al. | CD 34‐derived dendritic cells transfected ex vivo with HIV‐G ag m RNA induce polyfunctional T‐cell responses in nonhuman primates | |
| CN112313328B (zh) | 用于治疗用途的树突细胞的体外分化和成熟方法 | |
| US20170321189A1 (en) | Co-Differentiation Of Monocytes From Allogeneic Donors | |
| Kim et al. | Two-step maturation of immature DCs with proinflammatory cytokine cocktail and poly (I: C) enhances migratory and T cell stimulatory capacity | |
| WO2010049152A1 (en) | Novel composition for the preparation of mature dendritic cells | |
| WO2025076176A2 (en) | Cross-presenting dendritic cells |